Skip to content

Predictive Biomarkers of Secondary Aggravation in Covid-19 Suspect Patient

Predictive Biomarkers of Secondary Aggravation in Covid-19 Suspect Patient Admitted to Emergency Departments During an Epidemic

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04341792
Acronym
BIOCOVU
Enrollment
373
Registered
2020-04-10
Start date
2020-04-11
Completion date
2020-11-12
Last updated
2025-12-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronavirus, COVID-19, Infection Viral

Keywords

infection viral, biological risk factor, coronavirus, covid-19

Brief summary

There is no predictive tool for patients admitted to the emergency department with a suspicion of Covid-19 that will worsen secondarily and require a heavy lifting. In a context of saturation of the healthcare system by the pandemic at Covid-19,it is essential to identify specific, accessible prognostic markers via minimally invasive sampling with low risk of infection for personnel caregiver, for optimal allocation of resuscitation resources. This study proposes to evaluate the biological markers of routine care known to be associated with resuscitation admission in relation to hospitalization on conventional service for the prediction of worsening of patients admitted to the emergencies for Covid-19.

Interventions

None listed

Sponsors

University Hospital, Lille
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Clinical criteria for suspicion of Covid-19 in an epidemic period * Consultation in the emergency departement * Non-opposition agree

Exclusion criteria

* impairment related to another identified cause than Covid-19, in particular a rapid diagnostic test flu-positive * Severe patient from the outset with transfer to intensive care within 12 hours of admission to the Emergency Department * No social security coverage (beneficiary or entitled person) * Poor understanding of French * Refusal to participate

Design outcomes

Primary

MeasureTime frameDescription
Rate of secondary aggravationan average at 30 days (- 2 days +3 days) of admission to the emergency departmentSecondary aggravation is defined as : * a re-hospitalization or * aggravation in hospitalization : development or increase in oxygen dependency, hemodynamic failure, and/or respiratory, death

Secondary

MeasureTime frameDescription
Change of standart biological parametersBetween baseline and an average at 30 days (- 2 days +3 days) of admission to the emergency departmentthe number of leukocytes, lymphocytes, neutrophil polynuclear cells, CRP, fibrinogen, and the D-dimers.
Change of Von willebrand factor (vWF) changes over timeBetween baseline and an average at 30 days (- 2 days +3 days) of admission to the emergency department
Change of the Factor VIII (FVIII)Between baseline and an average at 30 days (- 2 days +3 days) of admission to the emergency department
Prevalence of positivity of COVID-19 virus measured by PCR or serologyan average at 30 days (- 2 days +3 days) of admission to the emergency department

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026